Journals / Medicine Science / 2013 / Cilt: 2 Sayı: 2

Investigating the Efficacy and Safety of Silymarin in Management of Hyperbilirubinemia in Neonatal Jaundice

Pages
575–590
Publication Date
2013-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Silymarin dose of 3.75mg/kg twice daily along with phototherapy was more effective than phototherapy alone in treating full term healthy neonates with UCB.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Unconjugated hyperbilirubinemia (UCB) is one of the most common conditions in neonates.
📊
Key Findings & Data:Exchange transfusion is associated with a significant morbidity and even mortality.
💡
Conclusion & Impact:Silymarin dose of 3.75mg/kg twice daily along with phototherapy was more effective than phototherapy alone in treating full term healthy neonates with UCB.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:silymarin · neonatal jaundice · hyperbilirubinemia

Abstract

Unconjugated hyperbilirubinemia (UCB) is one of the most common conditions in neonates. Conventional treatment consists of phototherapy and exchange transfusion. Phototherapy is safe and effective but it has several disadvantages. Exchange transfusion is associated with a significant morbidity and even mortality. That indicates the need to develop an alternative pharmacological treatment strategies. It should be less invasive and at least as effective and safe as phototherapy. Herbal therapy has recently received special attention. Silymarin herbal drug has laxative, antioxidant, anti-inflammatory, hepatic protective, regenerative and enhancing of glucoronidation activities. The study presented here aimed to investigate effect of Silymarin on duration of phototherapy. A prospective cohort trial performed on 170 full term healthy neonates with UCB, 85 received oral 3.75mg/kg of Silymarin twice daily plus phototherapy and 85 neonates received only phototherapy. Total serum bilirubin (TSB) was measured every 24h, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and albumin were measured before and after therapy for both groups. The mean duration of phototherapy was found to be significantly reduced from 5.3 ± 0.82 days in the control group to 4.2 ± 0.76 days in Silymarin-treated group (p=0.001). ALT, AST are improved to normal levels significantly (p=.001) also albumin (p=0.005). Silymarin dose of 3.75mg/kg twice daily along with phototherapy was more effective than phototherapy alone in treating full term healthy neonates with UCB.

🔖

Cite This Article

Kassem, L. M., Abdelrahim, M. E., Naguib, H. F. (2013). Investigating the Efficacy and Safety of Silymarin in Management of Hyperbilirubinemia in Neonatal Jaundice. Medicine Science, Cilt: 2 Sayı: 2, 575–590. https://ajindex.com/articles/1003308

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Cohen RS, Wong RJ, Stevenson DK. Understanding neonatal jaundice: a perspective on causation. Pediatrics & Neonatology. 2010;51(3):143-8. doi: 10.1016/S1875- 9572(10)60027-7 2. Cloherty JP, Eichenwald EC, Stark AR, eds. Manual of Neonatal Care. 6 ed. 2008;181-212. 3. Stevenson DK, Vreman HJ, Oh W, Fanaroff AA, Wright LL, Lemons JA, Verter J, Shankaran S, Tyson JE, Korones SB, Bilirubin production in healthy term infants as measured by carbon monoxide in breath. Clinical chemistry. 1994;40(10):1934-9. 4. Yudkin S, Gellis SS. Liver function in newborn infants with special reference to excretion of bromsulphalein. Archives of disease in childhood. 1949; 24(117):12-4. 5. Tazawa Y, Abukawa D, Watabe M, Nakagawa M, Yamada M. Abnormal results of biochemical liver function tests in breast-fed infants with prolonged indirect hyperbilirubinaemia. European journal of pediatrics. 1991;150(5):310-3. 6. Bhutani, VK, Johnson LH, Maisels MJ, Newman TB, Phibbs C, Stark AR, YearginAllsopp M. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. Journal of perinatology. 2004;24(10):650-62. 7. Maisels M. Physiologic jaundice. Avery's Neonatology Pathophysiology & Management of the Newborn. 6th Edition. Philedelphia Lippincott Saunders. 2005;768-846. 8. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001;344(8):581-90. 9. Dennery PA. Pharmacological interventions for the treatment of neonatal jaundice. Elsevier. 2002. 10. Avery GB, MacDonald MG, Seshia MMK, Mullett MD, Avery's neonatology: pathophysiology & management of the newborn. Lippincott williams & wilkins. 2005. 11. Tiribelli C, Ostrow JD, New concepts in bilirubin and jaundice: Report of the Third International Bilirubin Workshop, April 6‐8, 1995,
  2. Trieste, Italy. Hepatology. 1996;24(5):1296-311. 12. Cuperus F, Hafkamp A, Hulzebos C, Verkade H. Pharmacological therapies for unconjugated hyperbilirubinemia. Current Pharmaceutical Design. 2009;15(25):2927- 38. 13. Tamayo C, Diamond S. Review of Clinical Trials Evaluating Safety and Efficacy of Milk Thistle (Silybum marianum [L.] Gaertn.). Integrative cancer therapies. 2007;6(2): 146-57. 14. Morazzoni P, Bombardelli E. Silybum marianum (fitoterapia). Fitoterapia. 1995;66:3- 42. 15. Křen V Walterová D. Silybin and silymarin--new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005 Jun;149(1):29-41. 16. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatiti